Queen Mary University of London: Breast Neoplasms trials

The registry lists 12 Breast Neoplasms studies with Queen Mary University of London as lead sponsor. 1 are open to participants now and 1 have results posted.

Phase 2 6Phase 3 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast CancerRecruitingNCT06954480Phase 2
• Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In SituCompletedNCT00072462Phase 3Results posted
• An Imaging Study in ER Negative Breast Cancer by Targeting αvβ6WithdrawnNCT06978478Not applicable
• Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast CancerWithdrawnNCT03841747Phase 2
• Pre-operative Immunotherapy Combination Strategies in Breast CancerCompletedNCT03395899Phase 2
• Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast CancerCompletedNCT02676986Phase 2
• PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerCompletedNCT02423603Phase 2
• A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerCompletedNCT02216786Phase 2
• Long-term Anastrozole Versus Tamoxifen Treatment EffectsCompletedNCT01745289
• Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy VolunteersStatus unknownNCT00935233
• Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast CancerCompletedNCT00078832Phase 3
• Tamoxifen for the Prevention of Breast Cancer in High-Risk WomenCompletedNCT00002644Phase 3